NCT02315612 2026-03-24
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company